+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

M

Actively Recruiting

This research aims to evaluate the safety and effectiveness of ELAPR002f injectable gel in adults with moderate to severe atrophic acne scars. These scars are flat or indented marks that remain after acne heals and can affect quality of life through reduced self-esteem and embarrassment. The study is a controlled, randomized trial including about 395 adults with scarring on both cheeks, conducted at multiple sites in the United States. Participants are divided into two cohorts. Cohort 1 receives ELAPR002f injectable gel openly, while Cohort 2 participants are randomly assigned to receive either ELAPR002f gel or a saline control via intradermal injections. Treatments are given on Days 1, 31, and 61. After the three treatment sessions over two months, participants are followed for up to 12 months to observe outcomes and any side effects. During the study, participants will have regular visits at a clinic or hospital for medical assessments, blood tests, and questionnaires to monitor their progress and any side effects. Researchers will measure the percentage of participants who achieve at least a 20% reduction in acne scar area and various safety parameters, including injection site responses and changes in vital signs and laboratory values. The total study duration for each participant can be up to 420 days.

Age: 22Years +All GendersPhase 3
10 locations
R

Actively Recruiting

Researchers are collecting real-world data on the use of the commercially approved Intracept10 Intraosseous Nerve Ablation Systems to treat patients diagnosed with vertebrogenic pain, including those with chronic low-back pain and vertebrogenic pain syndrome. The study aims to better understand outcomes from this minimally invasive procedure in routine clinical settings. Participants will receive treatment with the Intracept10 Intraosseous Nerve Ablation device following local instructions for use. The study observes patients who undergo this nerve ablation therapy without assigning participants to different groups, as it is an observational study without randomization or placebo. Throughout the study, participants will be monitored over 60 months after the procedure. Researchers will assess changes in disability using the Oswestry Disability Index ODI and gather other outcome data to evaluate the impact of treatment. Participation involves regular follow-up to document treatment effects and safety over time.

Age: 18Years +All Genders
22 locations
S

Actively Recruiting

Researchers are studying the use of autologous bone marrow derived stem cells BMSC to improve neurologic function in patients with various neurologic disorders and diseases. This study focuses on neurologic conditions that have caused functional damage unlikely to improve with current standard treatments. The trial aims to add to existing knowledge about the potential benefits of BMSC treatment, particularly using intravenous and intranasal delivery methods targeting the central nervous system. Participants receive treatment involving the collection of their own bone marrow stem cells, which are then separated and administered both intravenously and applied topically to the lower third of the nasal passages. This dual delivery approach is designed to help the stem cells reach areas of the brain via the bloodstream and along the trigeminal nerve pathways. The treatment is given as a single intervention with follow-up evaluations at multiple time points. During the study, participants will undergo neurological assessments at baseline and at 1, 3, 6, and 12 months after treatment to monitor changes in neurological function. Medical stability and ongoing safety will be evaluated by the participants primary care doctor and neurologists. The study will measure improvements in neurologic function and monitor any effects or risks related to the stem cell procedure over the course of one year following treatment.

Age: 18Years +All GendersPhase Not Applicable
3 locations
S

Actively Recruiting

Researchers are evaluating the use of autologous bone marrow derived stem cells BMSC to treat vision loss caused by retinal or optic nerve damage that is typically considered irreversible. The study focuses on conditions such as macular degeneration, hereditary retinal dystrophies like retinitis pigmentosa and Stargardt disease, ischemic or physical retinal damage, as well as optic nerve damage from glaucoma, ischemic optic neuropathy, optic atrophy, and other related diseases. Participants will receive injections of their own stem cells isolated from bone marrow using standard medical and surgical procedures. These injections may be given retrobulbarly, subtenon, intravitreal, intraocular, subretinal, and intravenously to one or both eyes. The treatment is provided in a single group format, and patients will be monitored for 12 months following the procedure. During the 12-month follow-up, participants will undergo comprehensive eye exams including imaging and diagnostic ophthalmic tests. Researchers will measure changes in visual acuity, visual fields, and optical coherence tomography results from before the procedure to 12 months after. Safety and treatment effects will be closely monitored through these assessments to evaluate the potential benefits and risks of the stem cell therapy.

Age: 18Years +All GendersPhase Not Applicable
4 locations
S

Actively Recruiting

Healthy Volunteer

This research is focused on individuals seeking chin augmentation to improve chin profile. It aims to evaluate the safety of retreatment with Restylane Lyft with Lidocaine, a dermal filler device made of sterile hyaluronic acid gel, specifically 3 months after an optional retreatment given 12 months after the last treatment. The study is interventional and sponsored by Galderma R&D, targeting adults aged 22 and older. Participants will receive initial treatment with Restylane Lyft with Lidocaine in the chin region at baseline. They may have an optional touch-up treatment one month after the initial procedure and an optional retreatment 12 months after the last treatment. The retreatment safety will be assessed up to 3 months following this last retreatment. During the study, participants will be monitored for treatment-emergent adverse events related to the device or injection procedure after the optional retreatment period. The main outcome measure is the number of participants experiencing such adverse events from month 12 to month 15. The total participation duration includes initial treatment, optional touch-up, optional retreatment, and safety observation following retreatment.

Age: 22Years +All GendersPhase Not Applicable
8 locations